The rationale behind the study is straightforward. In healthy individuals, the immature platelet fraction typically accounts for only a small percentage of all platelets, and it rises when the marrow is under pressure to replenish circulating platelets, for example after chemotherapy or in immune thrombocytopenia. In myelodysplastic syndromes, however, the marrow is intrinsically dysfunctional, and the relationship between platelet production and clinical outcome is far less predictable. If a high IPF reflects compensatory but ineffective platelet output, or if it signals biologically more aggressive disease, then the measurement might help clinicians identify patients at higher risk of leukemic transformation or death. Conversely, if the IPF adds nothing beyond established scoring systems, its clinical use would need to be reconsidered.

To address these questions, the researchers designed a two-part investigation. The retrospective arm drew on 364 patients with myelodysplastic syndromes whose baseline IPF values and clinical courses were available from hospital records. The prospective arm enrolled 46 patients under a registered observational protocol, identified as UMIN000057807, in whom the investigators followed outcomes forward in time with standardized assessments. The primary endpoint in both analyses was leukemia-free survival, a composite measure defined as the time until either transformation to acute myeloid leukemia or death from any cause. Secondary endpoints included overall survival and, among patients treated with the hypomethylating agent azacitidine, the rate of hematological improvement.

The retrospective results provided the first hint that the IPF might carry prognostic weight. Using a cutoff of 6.8 percent, the researchers divided the 364 patients into low and high IPF groups and found that 50 leukemia-free survival events occurred during follow-up. Patients whose baseline IPF exceeded 6.8 percent experienced significantly shorter leukemia-free survival and shorter overall survival in unadjusted analyses, with log-rank p values of 0.033 and 0.022 respectively. In a univariable model, a high IPF was associated with a hazard ratio of 1.79 for leukemia-free survival, meaning a roughly 79 percent increase in the risk of leukemic transformation or death, with a 95 percent confidence interval spanning 1.02 to 3.16.

Prognostic research, however, demands caution before celebrating any single variable, and the adjusted analyses told a more nuanced story. When the investigators controlled for age, platelet count, and the Revised International Prognostic Scoring System, a widely used risk stratification tool in myelodysplastic syndromes, the association retained a similar magnitude but lost statistical significance. The adjusted hazard ratio for leukemia-free survival was 2.02, with a 95 percent confidence interval of 0.98 to 4.18 and a p value of 0.057, sitting just at the threshold of conventional significance. The point estimate actually grew larger after adjustment, suggesting the IPF may capture information beyond standard scores, but the wide confidence interval reflects the limited number of events and leaves the conclusion uncertain. The discriminatory performance of the continuous IPF was likewise modest, with a two-year time-dependent area under the curve of 0.638 and a 95 percent confidence interval of 0.561 to 0.715, well short of the near-perfect separation clinicians would want from a standalone biomarker.

The study also probed the biological meaning of the IPF by comparing it with direct examination of the bone marrow. The continuous IPF value showed a moderate correlation with the bone marrow megakaryocyte count, quantified by a Spearman’s rank correlation coefficient of 0.50 with a p value below 0.001. Interestingly, however, the median megakaryocyte counts were identical across the high and low IPF groups, indicating that the correlation, while statistically robust, did not translate into a simple categorical distinction. This pattern suggests that the IPF reflects not merely how many megakaryocytes populate the marrow but how productively those cells release platelets, a functional dimension that conventional morphology may miss in dysplastic marrow.

The prospective cohort was intended to test these retrospective signals under more controlled conditions, and here the picture shifted. Among the 46 prospectively enrolled patients, overall survival and leukemia-free survival did not differ between those with an IPF at or below 6.8 percent and those above the threshold, with log-rank p values of 0.929 and 0.402 respectively. The explanation lies partly in the numbers: only three deaths and four leukemia-free survival events occurred in this small cohort, far too few to detect anything but a dramatic effect. Exploratory prospective studies of this size are inherently underpowered, and the absence of a difference should be read as inconclusive rather than as evidence that the IPF is prognostically irrelevant.

The azacitidine analysis added a therapeutic dimension to the investigation. Azacitidine, a hypomethylating agent, is a mainstay of treatment for higher-risk myelodysplastic syndromes, yet responses vary considerably between patients, and clinicians lack reliable predictors of who will benefit. Among response-evaluable patients treated with azacitidine, hematological improvement occurred in 4 of 14 patients, or 28.6 percent, in the high IPF group, compared with 5 of 8 patients, or 62.5 percent, in the low IPF group. The difference is striking in relative terms but did not reach statistical significance, with a p value of 0.187, and the tiny denominators make any interpretation speculative. Still, the direction of the effect raises the possibility that a high IPF, perhaps signaling more severely disordered thrombopoiesis, could be associated with reduced responsiveness to azacitidine, a hypothesis that only adequately powered trials can confirm or refute.

The authors are careful to frame the IPF as an investigational biomarker rather than a validated clinical tool, and their caution is warranted. The measurement itself is attractive: it is generated automatically by modern hematology analyzers using fluorescent dyes or equivalent technologies that stain RNA-rich reticulated platelets, requires no additional blood draw, and delivers results within the routine complete blood count workflow. Yet the present study demonstrates the classic challenges of biomarker research in rare malignancies. The retrospective signal was genuine but weakened after adjustment for established prognostic factors, the prospective cohort was too small to confirm or refute it, and the discriminatory capacity of the marker was modest at best. The investigators explicitly call for validation in adequately powered multicenter cohorts, which would allow event numbers sufficient for stable adjusted estimates and subgroup analyses across disease risk categories.

For patients and clinicians, the takeaway is one of tempered interest rather than immediate practice change. The immature platelet fraction is not yet ready to join the Revised International Prognostic Scoring System or molecular risk panels in guiding treatment intensity or transplant decisions. What the study does establish is a credible biological and statistical foundation for continued investigation: a plausible mechanism linking platelet turnover to disease behavior, a reproducible retrospective association, and a prospectively collected dataset that can inform the design of larger studies. As flow cytometry-derived and analyzer-derived markers of hematopoietic stress accumulate, the IPF may ultimately find its place alongside other measures in a composite prognostic model. Until such validation arrives, the 6.8 percent threshold remains a research cutoff, not a clinical decision point, and patients with myelodysplastic syndromes will continue to be risk-stratified by the established tools that decades of evidence have validated.

Subject of Research: Prognostic value of the immature platelet fraction in myelodysplastic syndromes

Article Title: The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment

Article References: Yamasaki, S., Hashiguchi, M., Yoshida-Sakai, N., Jojima, H., Osaki, K., Okamura, T., & Imamura, Y. (2026). The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment. Annals of Hematology. https://doi.org/10.1007/s00277-026-07270-z

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07270-z

Keywords: myelodysplastic syndromes, immature platelet fraction, biomarker, prognosis, azacitidine, acute myeloid leukemia, leukemia-free survival, thrombopoiesis, megakaryocytes, hematology, prospective cohort study, Revised International Prognostic Scoring System

The stakes are higher than the word platelet might suggest. As people age, their platelets become hyperreactive, aggregating more readily and contributing to the elevated risk of heart attacks and strokes in older adults. Megakaryocytes sit at the origin of that problem. These enormous cells, which can contain up to 64 copies of the genome, undergo a metabolically demanding maturation program before shedding platelets into the bloodstream. Aging impairs their proliferation, differentiation, and quality-control machinery through both intrinsic cellular defects and changes in the bone marrow environment. Yet the precise molecular drivers of megakaryocyte decline during natural aging have remained poorly defined, and no targeted nutritional intervention had been shown to reverse it.

The research team, led by investigators affiliated with the Sun Yat-sen University Health System, took an unusually rigorous approach for a nutrition study. Rather than relying on accelerated genetic aging models, they used naturally aged male C57BL/6J mice, dividing 84 animals into cohorts starting at 1, 9, 15, 19, 21, and 23 months of age. Each cohort received either a control diet or the same diet supplemented with CoQ10 at 550 milligrams per kilogram of chow for 12 weeks, a dose the authors calculate as roughly equivalent to 300 milligrams per day for a 60-kilogram adult. The mice were then analyzed at 4, 12, 18, 22, 24, and 26 months of age, spanning nearly the entire murine lifespan.

The systemic effects of the supplement were clear and age-dependent. CoQ10-treated mice showed reduced levels of reactive oxygen species and malondialdehyde, a marker of lipid peroxidation, along with increased total antioxidant capacity and higher activity of the antioxidant enzymes superoxide dismutase, catalase, and glutathione. Chronic inflammation, the smoldering fire that accompanies aging, also receded: plasma concentrations of the inflammatory cytokines IL-6, TNF-alpha, and IL-1beta were significantly lower in supplemented animals, with IL-1beta dropping as early as 12 months. Circulating klotho, a protein whose decline is closely associated with aging, was modestly preserved, reaching statistical significance at 24 months. Notably, blood levels of ubiquinol and ubiquinone, the two forms of CoQ10, rose most clearly in mice older than 22 months, suggesting the biological effects of supplementation become most pronounced in advanced age, when endogenous CoQ10 availability has waned.

Within the bone marrow, the changes were striking. Colony-forming assays revealed that megakaryocytes from CoQ10-fed mice proliferated more vigorously, forming larger and more numerous colonies at 12, 16, and 18 months. Flow cytometry showed increased proportions of cells expressing the maturation markers CD41 and CD61, and ploidy analysis revealed a shift toward highly polyploid 16N, 32N, and 64N megakaryocytes, the fully mature end-stage cells most capable of platelet production, whereas control animals accumulated predominantly 8N cells. Apoptosis among megakaryocytes, which rises with age, was significantly reduced in the supplemented groups at 22, 24, and 26 months.

The mechanistic thread connecting these improvements was autophagy, the conserved intracellular recycling process by which cells digest damaged proteins and organelles. Autophagic activity declines with age across many tissues, and in the megakaryocytes of naturally aged mice the researchers observed exactly that pattern: the ratio of lipidated LC3-II to LC3-I, a standard readout of autophagosome formation, fell progressively, while the cargo receptor p62 accumulated. Twelve weeks of CoQ10 reversed both markers at nearly every age examined. Because LC3 and p62 were measured under steady-state conditions in the animal experiments, the authors are careful to note that these data indicate altered autophagic activity but do not by themselves prove enhanced autophagic flux in vivo.

To find the molecular link, the team turned to unbiased quantitative proteomics using Astral DIA mass spectrometry on megakaryocytes isolated from 24-month-old mice. Among the proteins upregulated by CoQ10, one stood out: COPS3, a core subunit of the COP9 signalosome, an evolutionarily conserved complex that regulates protein stability by deneddylating Cullin-RING ubiquitin ligases. In fact, the proteomic data showed that COPS3 was the most highly represented protein within the biological process of protein deneddylation, and several other COP9 subunits rose in parallel. Western blotting across the age series confirmed that COPS3 expression declines gradually with age and that CoQ10 supplementation significantly restores it, particularly at 24 months. Because the COP9 signalosome governs ubiquitin signaling, which is intricately intertwined with autophagy regulation, COPS3 offered a plausible bridge between the supplement and the cellular cleaning crew.

Cell-culture experiments in senescent MEG-01 human megakaryocytic cells, driven into senescence with hydrogen peroxide, put the hypothesis to the test. CoQ10 treatment raised COPS3 levels and shifted the autophagy markers in the direction of enhanced flux, and these effects persisted even when autophagy was pharmacologically blocked with LY294002. Critically, when the researchers silenced COPS3 with siRNA, the CoQ10-induced increase in the LC3-II/LC3-I ratio, the reduction in p62, and the improvements in maturation-marker expression and polyploidization were all partially attenuated. A bafilomycin A1 turnover assay, which blocks lysosomal degradation and thereby reveals how much LC3-II is actually being delivered to lysosomes, provided direct evidence that CoQ10 enhances autophagic flux rather than merely causing autophagosomes to pile up. The incomplete rescue after COPS3 knockdown tells an honest story: COPS3 is a functional contributor to CoQ10’s effects, but not their sole mediator, and gain-of-function and rescue experiments remain to be done.

The downstream consequence for platelet biology is perhaps the most clinically tantalizing finding. Collagen-induced platelet aggregation, which rises with age and peaks before declining at the very oldest ages, was significantly suppressed in CoQ10-fed mice from 18 through 26 months. Activation markers CD62P and JON/A, an antibody that reports the active conformation of the integrin alphaIIb-beta3, were similarly reduced. Importantly, these benefits came without apparent costs: platelet counts, reticulated platelet percentages, and tail-bleeding times were unchanged, suggesting the supplement tames platelet hyperreactivity without crippling primary hemostasis. The authors caution, however, that tail-bleeding time is a crude measure of hemostasis and that these results should not be read as evidence that CoQ10 prevents thrombosis in older adults.

The study is candid about its limits. The mechanistic cell work used an induced senescence model rather than primary megakaryocytes, the in vitro CoQ10 concentration of 100 micromolar exceeds what oral supplementation typically achieves in blood, only a single dietary dose was tested, and only male mice were studied, leaving open whether females respond similarly. How CoQ10, a molecule best known for shuttling electrons inside mitochondria, signals to the nucleus to raise COPS3 expression remains unresolved, though prior work showing that CoQ10 modulates Nrf2 and NF-kappaB-dependent transcription offers plausible routes. Even with those caveats, the convergence of a lifespan-scale dietary intervention, proteomic discovery, genetic knockdown, and flux assays makes a compelling case that CoQ10 supports proteostatic resilience in aging megakaryocytes through a COPS3-autophagy axis. For a supplement often dismissed as scientifically soft, that is a remarkably concrete mechanism, and it points toward nutritional strategies for the platelet dysfunction of aging that now deserve proper clinical scrutiny.

Subject of Research: Effects of dietary coenzyme Q10 on age-related megakaryocyte dysfunction via COPS3-mediated autophagy activation

Article Title: Dietary CoQ10 Ameliorates Age‐Related Megakaryocyte Dysfunction via COPS3‐Mediated Activation of Autophagy

Article References: Xu, Y., Mao, Y.-H., Song, F., He, F., Wu, Y., Wang, C., Wang, M., Xie, S., Ni, H., & Yang, Y. (2026). Dietary CoQ10 Ameliorates Age‐Related Megakaryocyte Dysfunction via COPS3 ‐Mediated Activation of Autophagy. Aging Cell, 25(10), Article e70726. https://doi.org/10.1111/acel.70726

Image Credits: AI Generated

DOI: 10.1111/acel.70726

Keywords: coenzyme Q10, megakaryocytes, autophagy, COPS3, COP9 signalosome, aging, platelets, oxidative stress, inflammaging, bone marrow, proteomics, Aging Cell

CTIT is a common and clinically consequential hematologic toxicity in patients with solid tumors. Chemotherapy, radiotherapy, and targeted agents can all suppress the bone marrow’s ability to produce platelets, the small cell fragments that form clots and prevent hemorrhage. When platelet counts fall below safe thresholds, oncologists are frequently forced to postpone or reduce doses of anti-cancer drugs, compromising the very treatment meant to control the tumor. In severe cases, spontaneous bleeding can become life-threatening. Platelet transfusions and standard TPO-RA monotherapy help many patients, but a subset remains refractory, with counts that stay dangerously low despite every conventional measure.

The research team, led by Lin-Ya Wang and Fei-Fei Tang of the Peking University Institute of Hematology, set out to test whether adding ATRA to continued TPO-RA therapy could break through this resistance. Their rationale rests on platelet biology: TPO-RAs such as eltrombopag and romiplostim stimulate thrombopoietin receptors on megakaryocytes, the large bone marrow cells that shed platelets into the bloodstream, while ATRA is thought to promote megakaryocyte maturation and platelet production through complementary pathways, including retinoid signaling and effects on the bone marrow microenvironment. Combining the two agents, the investigators reasoned, might attack the problem from two directions at once.

The study retrospectively analyzed 28 patients with refractory CTIT, defined as grade 2 or worse thrombocytopenia according to the CTCAE v5.0 criteria despite prior TPO-RA therapy. All patients were treated at Peking University People’s Hospital between August 2023 and May 2025. Each received oral ATRA at a dose of 25 milligrams per square meter of body surface area daily for six weeks, alongside continued TPO-RA treatment. The severity of the starting condition was sobering: the median baseline platelet count was just 13 × 10⁹ per liter, with individual values ranging from a perilous 2 × 10⁹ to 69 × 10⁹ per liter. Counts at that level leave patients exposed to serious bleeding risk and effectively rule out continued cancer therapy.

The results were unambiguous. Platelet counts climbed steadily from baseline after treatment began, with median elevations of +17 × 10⁹ per liter by day 14 (P = 3.05 × 10⁻⁵), +36 × 10⁹ per liter by day 28 (P = 9.54 × 10⁻⁷), and +59 × 10⁹ per liter by day 42 (P = 7.45 × 10⁻⁹). By the end of the observation window, the median patient had gained nearly five times their starting platelet count. Twelve patients, or 42.9 percent, achieved a complete response, defined as recovery to normal platelet levels, while another seven patients, 25.0 percent, achieved a partial response. The overall response rate stood at 67.9 percent, meaning roughly two of every three patients who had failed standard therapy regained usable platelet counts. The median time to complete response was 31 days, with responses occurring as early as 12 days and as late as 40 days after starting the combination.

Safety data were equally encouraging. ATRA is not a benign molecule; it carries known risks of liver enzyme elevation, headache, and, in the setting of acute promyelocytic leukemia, a potentially dangerous complication called differentiation syndrome. Yet in this population, the combination was well tolerated. Only four patients, 14.3 percent, developed elevated liver enzymes, three of them grade 1 and one grade 2, and three patients, 10.7 percent, experienced mild, grade 1 nausea. Critically, no grade 3 or higher adverse events were recorded, no thrombotic events occurred, and no patient developed differentiation syndrome. For a drug that stimulates platelet production, the absence of clotting complications is a particularly important signal, since raising platelet counts in cancer patients could theoretically tip the balance toward thrombosis.

The study also uncovered intriguing patterns in who responded best. Within the female cohort, patients with tumors of the female reproductive system responded significantly more poorly than those with other cancers: their overall response rate was 57.1 percent compared with 100.0 percent for non-FRS tumors (P = 0.038), and none of the FRS tumor patients achieved a complete response versus 70.0 percent of the others (P = 0.008). The authors also noted trends toward inferior complete response rates among patients with a history of radiotherapy (P = 0.057) and those treated with paclitaxel (P = 0.054), neither of which reached statistical significance in this small sample. These signals suggest that the biology of refractory CTIT may differ depending on the tumor type and prior treatment exposures, and that certain patient groups may need alternative or intensified strategies.

One of the most mechanistically revealing findings involved the bone marrow itself. Patients whose baseline bone marrow biopsies showed higher megakaryocyte counts, at least five per high-powered field, exhibited a trend toward higher overall response rates compared with those with lower counts, 76.5 percent versus 54.5 percent, though the difference did not reach statistical significance (P = 0.41). The observation makes biological sense: megakaryocytes are the cellular factories of platelets, and a marrow that retains a reasonable supply of these cells is more likely to respond to drugs that push them into overdrive. Conversely, patients whose marrows have been devastated by chemotherapy or radiotherapy may lack the raw cellular substrate needed for any platelet-boosting strategy to succeed. If confirmed in larger cohorts, megakaryocyte counts could help clinicians identify which refractory patients are most likely to benefit from the ATRA-plus-TPO-RA combination before committing to six weeks of therapy.

The study’s design demands careful interpretation. As a retrospective, single-center analysis of 28 patients, it cannot rule out selection bias, and without a randomized control group it is impossible to say with certainty how many patients would have recovered on continued TPO-RA monotherapy alone. The authors themselves frame the work as hypothesis-generating. Nevertheless, the magnitude and tempo of the platelet recoveries, the near-complete absence of serious toxicity, and the internal consistency of the response kinetics give the findings considerable weight. A prospective randomized trial will be needed before the combination can be recommended as standard of care, but for a population with essentially no good options, the bar for moving forward is low.

The broader significance extends beyond one drug pairing. CTIT is becoming an increasingly visible problem as cancer therapy grows more intensive and as patients live longer with advanced disease, and refractory cases consume transfusion resources while delaying tumor-directed treatment. The Peking University study suggests that rational combinations of agents targeting different nodes of thrombopoiesis, in this case retinoid-driven megakaryocyte maturation layered on top of thrombopoietin receptor stimulation, can rescue patients who were previously written off. It also revives interest in ATRA, a decades-old leukemia drug, as a repurposed agent in supportive oncology. If larger trials confirm these results, a cheap oral vitamin A derivative could become a standard partner for platelet-boosting drugs, keeping cancer treatment on schedule for thousands of patients whose platelets, and whose therapies, currently run out of road.

Subject of Research: Combination therapy with all-trans retinoic acid and thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia

Article Title: All-trans retinoic acid combined with thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia: a retrospective single-center study

Article References: Wang, L.-Y., Gao, H.-T., Fu, Q., Xu, L.-P., Zhang, X.-H., Huang, X.-J., & Tang, F.-F. (2026). All-trans retinoic acid combined with thrombopoietin receptor agonists for refractory cancer therapy-induced thrombocytopenia: a retrospective single-center study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07287-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07287-4

Keywords: all-trans retinoic acid, thrombopoietin receptor agonists, cancer therapy-induced thrombocytopenia, platelets, megakaryocytes, solid tumors, hematology, chemotherapy toxicity, Peking University, retrospective study, thrombopoiesis, drug safety